PRESS RELEASE published on 12/09/2025 at 07:30, 10 months 19 days ago OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
BRIEF published on 10/15/2025 at 19:05, 1 year ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
BRIEF published on 10/15/2025 at 19:05, 1 year ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
PRESS RELEASE published on 10/15/2025 at 19:00, 1 year ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE published on 10/15/2025 at 19:00, 1 year ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF published on 10/09/2025 at 16:02, 1 year ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
BRIEF published on 10/09/2025 at 16:02, 1 year ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
PRESS RELEASE published on 10/09/2025 at 15:57, 1 year ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 1 year ago OSE Immunotherapeutics : Réorganisation du Conseil d'administration Biotechnologie Conseil D'administration Immunothérapie OSE Immunotherapeutics Markus Cappel
Published on 10/28/2026 at 12:30, 16 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 16 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 16 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 16 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/28/2026 at 12:15, 31 minutes ago BULGOLD Expands Strategic Exploration Position Around the Lutila Gold Project with Two New Exploration Licences
Published on 10/28/2026 at 12:24, 22 minutes ago EQS-Adhoc: Ad-hoc | IVU Traffic Technologies AG: Earnings for the first nine months of 2026 were significantly higher than the previous year; full-year guidance reiterated
Published on 10/28/2026 at 12:21, 25 minutes ago HELIOS SOLAR AG Postpones Publication of Audited Annual and Consolidated Financial Statements as of 30 June 2026
Published on 10/28/2026 at 12:05, 41 minutes ago Bloomberg Introduces BQuant Assistant to Help Financial Professionals Accelerate Data Analysis and Coding Workflows
Published on 10/28/2026 at 11:49, 57 minutes ago OHB and Astroscale sign agreement to strengthen international cooperation on space security and orbital services capabilities
Published on 10/28/2026 at 11:34, 1 hour 12 minutes ago Logwin reports strong first nine-month results and updates outlook for 2026
Published on 10/28/2026 at 08:00, 4 hours 46 minutes ago Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 4 hours 46 minutes ago Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 18 hours 46 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 18 hours 46 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
